Concepedia

Author

Alison Reid

Institute of Cancer ResearchORCID

Also Known As

A H M Reid, A Reid, A. H. Reid, A. REID, A. Reid, A.H.M. Reid, Alison H M Reid, Alison H. M. Reid, Alison H. Reid, Alison H.M. Reid

55

Publications

4.1K

Citations

20

H-Index

37

Concepts

All Affiliations

Institute of Cancer ResearchRoyal Marsden NHS Foundation TrustRoyal Marsden HospitalUniversity of ManchesterChurchill Hospital
AR

About

Alison Reid is an author at Institute of Cancer Research specializing in medicine, oncology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

538

2

Arts

1

1

11

3

Public Health

1

1

11

4

Anesthesia

1

1

31

5

Communication

1

1

11

Alison Reid

×

21

Publications

3.6K

Citations

17

H-Index

YearCitations

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Gerhardt Attard, Alison Reid, Timothy A. Yap,

Journal of Clinical Oncology

2008

893

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

Gerhardt Attard, Alison Reid, Roger A’Hern,

Journal of Clinical Oncology

2009

600

Characterization of <i>ERG</i> , <i>AR</i> and <i>PTEN</i> Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

Gerhardt Attard, Joost F. Swennenhuis, David Olmos,

Cancer Research

2009

531

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

Alison Reid, Gerhardt Attard, Daniel C. Danila,

Journal of Clinical Oncology

2010

394

Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

Gerhardt Attard, Alison Reid, Richard J. Auchus,

The Journal of Clinical Endocrinology & Metabolism

2011

267

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

L. Rhoda Molife, Gerhardt Attard, Peter C.C. Fong,

Annals of Oncology

2009

181

Complex patterns of ETS gene alteration arise during cancer development in the human prostate

J Clark, Gerhardt Attard, Sameer Jhavar,

Oncogene

2007

148

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

David Olmos, Daniel Brewer, Jeremy Clark,

The Lancet Oncology

2012

116

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

L. Rhoda Molife, Peter C.C. Fong, Luisa Paccagnella,

British Journal of Cancer

2010

85

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

Sarah P. Blagden, L. Rhoda Molife, A Seebaran,

British Journal of Cancer

2008

80

Page 1